Suppr超能文献

一种冠状动脉穿孔紧急治疗的新策略:先置入药物洗脱支架,再用覆膜支架封闭渗漏以改善冠状动脉穿孔患者的长期预后

A Novel Strategy for Emergency Treatment of Coronary Perforations by Placing a Drug-Eluting Stent before Sealing off the Leakage with a Covered Stent to Improve Long-Term Outcomes in Patients with Coronary Artery Perforations.

作者信息

Ayoub Mohamed, Corpataux Noé, Tajti Péter, Behnes Michael, Schupp Tobias, Forner Jan, Akin Ibrahim, Westermann Dirk, Rudolph Volker, Mashayekhi Kambis

机构信息

Division of Cardiology and Angiology, Heart Center University of Bochum, 32545 Bad Oeynhausen, Germany.

Division of Cardiology, University Hospital Bern, 3010 Bern, Switzerland.

出版信息

J Pers Med. 2023 Oct 26;13(11):1542. doi: 10.3390/jpm13111542.

Abstract

We aimed to investigate the safety, feasibility, and long-term results of drug-eluting stent implantation before covered stents for treating coronary artery perforation (CAP). Between 2015 and 2020, 12,733 patients undergoing percutaneous coronary intervention (PCI) were retrospectively analyzed. The primary endpoint was 1-year target lesion revascularization (TLR), whereas secondary endpoints included the rate of major adverse cardiac and cerebrovascular events (MACCE) and all-cause death at 1 year. A total of 159 patients with CAP were identified during the study period, of whom 47.2% (n = 75) were treated with a covered stent (CS group) because of complex and/or severe CAP and 84 (52.8%) without (non-CS group). In the majority of patients, emergency drug-eluting stent placement before covered stent implantation was feasible (n = 69, 82%). There were no significant differences among patients treated with or without a covered stent in terms of primary or secondary clinical endpoints: a similar rate of TLR (18.67% vs. 21.43%, = 0.6646), MACCE (25.33% vs. 22.62%, = 0.6887), and 1-year mortality (12.00% vs. 11.90%, = 0.9853) were identified comparing cases with covered stent implantation and without. In conclusion, our study implicates that the use of covered stents for sealing coronary perforation might not impact the 1-year clinical outcome if used properly. Moreover, the emergent use of drug-eluting stents before covered stent implantation in CAP is a safe and effective method to avoid target lesion revascularization in patients treated with covered stents.

摘要

我们旨在研究在覆膜支架植入前应用药物洗脱支架治疗冠状动脉穿孔(CAP)的安全性、可行性和长期结果。回顾性分析了2015年至2020年间接受经皮冠状动脉介入治疗(PCI)的12733例患者。主要终点为1年靶病变血运重建(TLR),次要终点包括1年时主要不良心脑血管事件(MACCE)发生率和全因死亡率。在研究期间共识别出159例CAP患者,其中47.2%(n = 75)因复杂和/或严重CAP接受了覆膜支架治疗(CS组),84例(52.8%)未接受(非CS组)。在大多数患者中,在覆膜支架植入前紧急置入药物洗脱支架是可行的(n = 69,82%)。接受或未接受覆膜支架治疗的患者在主要或次要临床终点方面无显著差异:比较覆膜支架植入和未植入的病例,TLR发生率相似(18.67%对21.43%,P = 0.6646),MACCE发生率相似(25.33%对22.62%,P = 0.6887),1年死亡率相似(12.00%对11.90%,P = 0.9853)。总之,我们的研究表明,如果使用得当,应用覆膜支架封闭冠状动脉穿孔可能不会影响1年临床结局。此外,在CAP患者中,在覆膜支架植入前紧急使用药物洗脱支架是一种安全有效的方法,可避免接受覆膜支架治疗的患者发生靶病变血运重建。

https://cdn.ncbi.nlm.nih.gov/pmc/blobs/649f/10672714/27402f74ebcb/jpm-13-01542-g001.jpg

文献AI研究员

20分钟写一篇综述,助力文献阅读效率提升50倍。

立即体验

用中文搜PubMed

大模型驱动的PubMed中文搜索引擎

马上搜索

文档翻译

学术文献翻译模型,支持多种主流文档格式。

立即体验